Date: 2018-08-28
Type of information: Construction of new premises
Compound:
Company: SGS (Switzerland)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism: new laboratory for biopharmaceutical testing capabilities in Geneva
Disease:
Details:
- • On August 28, 2018, SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, announced it is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with a new 200m2 laboratory. The laboratory will be equipped with a number of state-of-the-art instruments, to respond to the growing need for biopharmaceutical studies during the early and late phase of characterization, as required by the ICH guidelines.
- Due to open by the end of Q3 2018, the new laboratory will complement the existing 800m2 facility and offer the new services for high order structure analysis of biologics, including circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC).
- When complete, the new laboratory will enable the Geneva facility – which opened in 1991 and is cGMP certified, GLP compliant and FDA inspected – to offer a full ICH Q6B physico-chemical characterization of biological products.
Financial terms:
Latest news:
Is general: Yes
